NEW YORK — The number that mattered most to Amgen investors on August 28, 2026 was not $299.87 (the closing price) but $38 billion: the approximate debt load Amgen carries after its 2023 acquisition of Horizon Therapeutics. When Federal Reserve Chair Kevin Warsh used the Jackson Hole stage to signal that rate relief will arrive later than markets had priced, biotech companies with large leveraged acquisition balance sheets felt the message acutely. Amgen Inc (NASDAQ: AMGN) closed down 0.38%, underperforming the broader Dow Jones Industrial Average, which finished the session at 53,559.99, a drop of 9.45 points.
The Horizon Therapeutics acquisition closed in October 2023 for $27.8 billion, the largest deal in Amgen’s 44-year history. The strategic rationale was straightforward: Horizon brought Tepezza, a biologic for thyroid eye disease generating roughly $1.8 billion annually, along with Krystexxa for gout and a pipeline of rare disease assets. Together, they extended Amgen’s revenue base into orphan drug markets where pricing power is structurally higher and competition structurally lower than in Amgen’s established cardiovascular and inflammatory disease portfolio.
Thirteen months since the deal closed, the integration is broadly on track. Tepezza revenue has stabilized after a temporary dip tied to reimbursement disputes with private insurers; those disputes were largely resolved by the second quarter of 2026. Amgen’s second-quarter 2026 results, reported in late July, showed total revenue of $9.2 billion, an increase of 8% year-over-year, with product sales growing across both the legacy Amgen portfolio and the Horizon assets. Executives guided for full-year revenue in the range of $37 billion to $38 billion.
Repatha, Amgen’s proprotein convertase subtilisin/kexin type 9 inhibitor for high cholesterol, added meaningful volume in the quarter as cardiovascular risk management became a more prominent focus among U.S. primary care physicians. The drug’s outcomes trial, published years ago, demonstrated a statistically significant reduction in major adverse cardiovascular events in high-risk patients; the translation from clinical evidence to prescribing volumes has been slower than Amgen initially projected, but the trajectory in 2025 and 2026 suggests that payer coverage expansion is now materializing into scripts. Peak sales estimates for Repatha range from $5 billion to $8 billion annually across analysts, with the current run rate still well below that ceiling.
The pressure from Warsh’s comments operates through two mechanisms for Amgen. The first is directly financial: Amgen’s floating-rate exposure on a portion of its acquisition debt means that a delay in rate cuts extends the cost of servicing that balance sheet. The second is valuation: biotechs with large net debt positions trade at a structural discount to peers in low-rate environments precisely because the free cash flow that could otherwise fund R&D or buybacks instead services leverage. Amgen’s free cash flow generation is substantial, approximately $7 billion to $8 billion annually, which provides meaningful coverage, but the direction of rate expectations shifts the market’s willingness to assign a premium multiple.
Amgen is also building a biosimilar business that some analysts view as structurally underappreciated. Biosimilars are lower-cost alternatives to branded biologics; Amgen has approvals for biosimilar versions of adalimumab (a copy of AbbVie’s Humira, the world’s best-selling drug for most of the past decade), bevacizumab, trastuzumab, and several other compounds. The biosimilar portfolio generated approximately $1.2 billion in the second quarter of 2026. Executives have argued that Amgen’s manufacturing expertise, honed over four decades of biologic production, gives it a durable cost advantage over pure-play biosimilar competitors.
The biotech sector broadly faces a different kind of rate sensitivity than technology or consumer discretionary stocks. Unlike speculative-stage biotechs, whose valuation depends almost entirely on the present value of distant future cash flows, Amgen is a profitable company with established products and near-term earnings visibility. Its 2026 earnings per share estimate, adjusted for amortization of acquisition intangibles, stands at approximately $22 to $24 per share. At $299.87, the stock trades at roughly 13 to 14 times that earnings estimate, a valuation that reflects the debt load and the execution risk of the Horizon integration, not the kind of terminal-value speculation that makes early-stage biotechs highly rate-sensitive.
That distinction mattered relatively little on August 28, when rate-driven sector rotation hit biotech as a category regardless of individual balance sheet quality. The session’s broad selloff in rate-sensitive sectors provided some context for the NVIDIA Corp (NVDA) decline of 3.4%, which reflected growth equity repricing rather than biotech dynamics specifically but illustrated the session’s broader character.
Amgen’s next significant scheduled catalyst is the presentation of pipeline data at major oncology and endocrinology conferences expected in the fall of 2026. Lumakras, Amgen’s KRAS G12C inhibitor for non-small cell lung cancer, is the subject of ongoing combination trials that could expand its addressable patient population significantly; early combination data with PD-1 inhibitors showed response rates that exceeded monotherapy expectations. Any positive data readout in that program would likely move the stock materially, independent of the macro backdrop. That uncertainty, unresolved as of August 28, is the primary reason Amgen shares do not fully reflect the underlying cash flow of its business. For broader analysis of the August 28 session context for Dow Jones components, see the AMZN stock today coverage of how the session unfolded across the index.
Related Posts
